Equity Overview
Price & Market Data
Price: $1.22
Daily Change: $0.00 / 0.00%
Daily Range: $1.10 - $1.27
Market Cap: $141,841,424
Daily Volume: 1,414,107
Performance Metrics
1 Week: -0.81%
1 Month: -15.86%
3 Months: 24.16%
6 Months: -2.40%
1 Year: 58.44%
YTD: 24.16%
Company Details
Employees: 161
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.